Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?

Interview: CEO Says He Welcomes Scrutiny, Competition

Executive Summary

Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.

You may also be interested in...



Coronavirus Update: AZ Gets $1bn From US, Secures Capacity For One Billion Vaccine Doses

Inovio vaccine data published, US government invests to protect, generic remdesivir launched in Bangladesh.

Coronavirus Update: Sanofi And GSK Unveil 'Unprecedented' Vaccine Alliance

Plus: Lilly unveils Olumiant COVID-19 study, Samsung and Vir to collaborate on antibody, Korean industry asks for government assistance.

Latecomer Merck Enters Coronavirus Vaccine Field With Themis Acquisition

While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.

Topics

Related Companies

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel